Given what I have seen so far, I am somewhat hopeful that timelines are now more than just empty words to fill ASX announcements and presentations, hence decided to look through and see what to expect in the next few months, especially with the Option deadline on 01/04/25 next year.
31 December 2023(for reference purposes) "The Company closed the quarter with $11.2m in cash. [...]"
April 2024Enrolment complete DFU (Phase 1) -
https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02792931-3A640107Quarterly Activity Statement
May-June 2024(estimated) Start recruitment Kidney Transplant (Phase 1/2b), externally funded, cost of product only -
https://onderzoekmetmensen.nl/en/trial/53310Additional trial sites in France, Italy, Lithuania, Spain (and likely more in the USA) start enrolling patients in HR aGvHD (Phase) -
https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02786853-3A639079July 2024Secondary endpoints DFU (Phase 1) -
https://clinicaltrials.gov/study/NCT05165628Quarterly Activity Statement
September 2024Primary Endoint DFU (Phase 1) -
https://clinicaltrials.gov/study/NCT05165628October 2024Annual report to shareholders
Quarterly Activity Statement
November 2024Final injection OA (Phase 3), externally funded, cost of product only -
https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=379726&isReview=true /
https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02753361-3A633137AGM
December 2024(estimated) Complete recruitment HR aGvHD (Phase 2) -
https://www.clinicaltrials.gov/study/NCT05643638January 2025(estimated) Primary endpoint HR aGvHD (Phase 2) -
https://www.clinicaltrials.gov/study/NCT05643638R&D Rebate (2023 $2.3 million)
Quarterly Activity Statement
February 2025Half-Year Financial Statements
March 2025(estimated, allowing 6 months/hopeful) Clinical study report DFU (Phase 1)
(estimate/hopeful) Update preclinical study heart disease, government grant - ASX announcement 26/09/22
https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02572301-3A603019, with the cells already encapsulated and delivered in July 2023 (taken from X, formerly known as Twitter):
April 202501/04/24 CYPOA expiring (potentially 18,177,637 x 30c = almost $5.5 million for the company, if the SP manages to get above 30c and makes it worthwhile converting them) -
https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02656017-3A616758 /
https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02672019-3A619351Quarterly Activity Statement
The above is a rough guide only. Feel free to add any additional dates/events or adjust where required.
(20min delay)
